IGF-1 and the muscle question The biggest worry with rapid weight loss is that some of what you lose is muscle, not fat
When stored outside recommended temperature ranges specified in FDA labeling, these medications may experience reduced efficacy, potentially leading to suboptimal glycemic control or inadequate weight management
Susan Sweeney, Executive Vice President of Obesity and Related Conditions, Amgen A Call for Compassionate Care For years, Stephens obsessed over the number on the scale
A weekly jab that melts kilos and balances blood sugar
To summarize, while it is already clear that GLP-1based therapies will be an integral part of the treatment of DKD owing to their metabolic, cardiovascular, and kidney effects, exciting times lie ahead, with the ongoing development of compounds that will have potentially greater effects on these outcomes, due to more pronounced effects on body weight and glycemia